Regulatory landscape

No FDA approval, and outside US compounding

No FDA-approved medicine contains ipamorelin. Novo Nordisk discovered it, Helsinn Therapeutics ran its two ileus trials, and development for ileus was reportedly discontinued after the published one disappointed. In the United States, FDA proposed in 2024 not adding it to the 503A bulks list, and its advisory committee voted against adding it that October. Understanding this status is essential to reading any claim about it honestly.

That landscape has since moved for other peptides but not for this one. In July 2026 the same advisory committee took up seven further peptides and, by narrow margins, recommended that FDA reclassify all but one of them. A recommendation is not a reclassification, and ipamorelin was not on that agenda at all, so nothing in that session changed its position. This unit covers why the sponsors left, the FDA compounding sequence, the anti-doping status under WADA, and how to read the research-chemical labeling that lets it still be sold.